Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease

Blood

Volumn 116, Issue 3, 2010, Pages 335-342

  Petrarca, Antonio ^a   Rigacci, Luigi ^b   Caini, Patrizio ^a   Colagrande, Stefano ^a   Romagnoli, Paolo ^a   Vizzutti, Francesco ^a   Arena, Umberto ^a   Giannini, Carlo ^a   Monti, Monica ^a   Montalto, Paolo ^c   Matucci Cerinic, Marco ^b   Bosi, Alberto ^a   Laffi, Giacomo ^a   Zignego, Anna Linda ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c Ospedale SS Cosma e Damiano   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; RITUXIMAB; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; VIRUS RNA;

ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CRYOGLOBULINEMIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEPATITIS C VIRUS; HUMAN; KIDNEY DISEASE; LEG ULCER; LIVER CIRRHOSIS; LIVER DISEASE; LIVER PARENCHYMA; LIVER STRUCTURE; MALE; POLYNEUROPATHY; PRIORITY JOURNAL; PURPURA; WEAKNESS; B LYMPHOCYTE; BLOOD; HEPATITIS C; IMMUNOLOGY; MIDDLE AGED; MONONUCLEAR PHAGOCYTE; PATHOLOGY; PROSPECTIVE STUDY; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; CRYOGLOBULINEMIA; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MONONUCLEAR PHAGOCYTE SYSTEM; PROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT OUTCOME;

EID: 77955915180     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-11-253948     Document Type: Article

References (42)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5(9):558-567. (Pubitemid 41196755)
2. Zignego AL, Brechot C. Extrahepatic manifestations of HCV infection: facts and controversies. J Hepatol. 1999;31(2):369-376. (Pubitemid 29349768)
3. Ferri C, Marzo E, Longombardo G, et al. Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood. 1993;81(5):1132-1136.
4. Zignego AL, Giannini C, Ferri C. Hepatitis C virus-related lymphoproliferative disorders: an overview. World J Gastroenterol. 2007;13(17):2467-2478. (Pubitemid 46929503)
5. Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB. Extrahepatic manifestations of hepatitis C virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis. 2007;39(1):2-17. (Pubitemid 46039435)
6. Zignego AL, Craxi A. Extrahepatic manifestations of hepatitis C virus infection. Clin Liver Dis. 2008;12(3):611-636, ix.
7. Lunel F, Musset L, Cacoub P, et al. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology. 1994;106(5):1291-1300. (Pubitemid 24129247)
8. Kayali Z, Buckwold VE, Zimmerman B, Schmidt WN. Hepatitis C, cryoglobulinemia, and cirrhosis: a meta-analysis. Hepatology. 2002;36(4 Pt 1):978-985.
9. Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood. 2003;101(10):3827-3834. (Pubitemid 36857853)
10. Petrarca A, Rigacci L, Monti M, et al. Improvement in liver cirrhosis after treatment of HCVrelated mixed cryoglobulinemia with rituximab. Dig Liver Dis. 2007;39(Suppl 1):S129-S133.
11. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol. 2007;46(1):160-170.
12. Andreone P, Gramenzi A, Cursaro C, Bernardi M, Zignego AL. Monoclonal gammopathy in patients with chronic hepatitis C virus infection [letter]. Blood. 1996;88(3):1122. (Pubitemid 26333340)
13. Zignego AL, Giannelli F, Marrocchi ME, et al. T(14;18) translocation in chronic hepatitis C virus infection. Hepatology. 2000;31(2):474-479. (Pubitemid 30078615)
14. Zignego AL, Ferri C, Giannini C, et al. Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia. Ann Intern Med. 1996;124(1 Pt 1):31-34. (Pubitemid 26019622)
15. Andreone P, Zignego AL, Cursaro C, et al. Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection. Ann Intern Med. 1998;129(4):294-298. (Pubitemid 28394574)
16. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24(2):289-293.
17. Gaiani S, Gramantieri L, Venturoli N, et al. What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. J Hepatol. 1997;27(6):979-985. (Pubitemid 27523955)
18. The Haemolytic Anaemias. 3rd ed. New York, NY: Churchill Livingstone; 2004.
19. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003;120(4):574-596.
20. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed lowgrade non-Hodgkin's lymphoma. Blood. 1997;90(6):2188-2195.
21. Grillo-Lopez AJ, Hedrick E, Rashford M, Benyunes M. Rituximab: ongoing and future clinical development. Semin Oncol. 2002;29(1 suppl 2):105-112. (Pubitemid 34173032)
22. Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood. 2003;101(10):3818-3826. (Pubitemid 36857852)
23. Zignego AL, Ferri C, Giannelli F, et al. Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med. 2002;137(7):571-580.
24. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646-649.
25. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996;23(1):164-176. (Pubitemid 26012105)
26. Giannini C, Giannelli F, Linda Zignego A. Association between mixed cryoglobulinemia, translocation (14;18), and persistence of occult HCV lymphoid infection after treatment. Hepatology. 2006;43(5):1166-1167. (Pubitemid 43724643)
27. Giannini C, Petrarca A, Monti M, et al. Association between persistent lymphatic infection by hepatitis C virus after antiviral treatment and mixed cryoglobulinemia. Blood. 2008;111(5):2943-2945.
28. Grazioli L, Bondioni MP, Romanini L, et al. Superparamagnetic iron oxide-enhanced liver MRI with SHU 555 A (RESOVIST): new protocol infusion to improve arterial phase evaluation - a prospective study. J Magn Reson Imaging. 2009;29(3):607-616.
29. Santoro L, Grazioli L, Filippone A, Grassedonio E, Belli G, Colagrande S. Resovist enhanced MR imaging of the liver: does quantitative assessment help in focal lesion classification and characterization? J Magn Reson Imaging. 2009;30(5):1012-1020.
30. Kato N, Ihara S, Tsujimoto T, Miyazawa T. Effect of resovist on rats with different severities of liver cirrhosis. Invest Radiol. 2002;37(5):292-298. (Pubitemid 34461675)
31. Tanimoto A, Yuasa Y, Shinmoto H, et al. Superparamagnetic iron oxide-mediated hepatic signal intensity change in patients with and without cirrhosis: pulse sequence effects and Kupffer cell function. Radiology. 2002;222(3):661-666. (Pubitemid 34215210)
32. Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992;305(6846):160- 164.
33. Quartuccio L, Soardo G, Romano G, et al. Rituximab treatment for glomerulonephritis in HCVassociated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology (Oxford). 2006;45(7):842-6.
34. Cavallo R, Roccatello D, Menegatti E, Naretto C, Napoli F, Baldovino S. Rituximab in cryoglobulinemic peripheral neuropathy. J Neurol. 2009;256(7):1076-1082.
35. Craxi A, Laffi G, Zignego AL. Hepatitis C virus (HCV) infection: A systemic disease. Mol Aspects Med. 2008;29(1-2):85-95.
36. Siagris D, Christofidou M, Tsamandas A, Lekkou A, Thomopoulos K, Labropoulou-Karatza C. Cryoglobulinemia and progression of fibrosis in chronic HCV infection: cause or effect? J Infect. 2004;49(3):236-241. (Pubitemid 39186170)
37. Monti G, Galli M, Invernizzi F, et al. Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias. QJM. 1995;88(2):115-126.
38. De Rosa FG, Abel G, Agnello V. Observations on cryoglobulin testing, II: the association of oligoclonal mixed cryoglobulinemia with cirrhosis in patients infected with hepatitis C virus. J Rheumatol. 2009;36(9):1956-1957.
39. McDonald V, Leandro M. Rituximab in non-haematological disorders of adults and its mode of action. Br J Haematol. 2009;146(3):233-246.
40. Leandro MJ, de la Torre I. Translational minireview series on B cell-directed therapies: the pathogenic role of B cells in autoantibody- associated autoimmune diseases-lessons from B cell-depletion therapy. Clin Exp Immunol. 2009;157(2):191-197.
41. Lamprecht P, Lerin-Lozano C, Merz H, et al. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis. 2003;62(12):1230-1233. (Pubitemid 37500635)
42. Saadoun D, Resche-Rigon M, Sene D, Perard L, Karras A, Cacoub P. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. Ann Rheum Dis. 2008;67(10):1431-1436.